The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
Abstract
Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients with prostate cancer, acquired resistance invariably emerges. To identify the molecular mechanisms underlying acquired resistance, we developed and characterized cell lines resistant to ARN-509 and enzalutamide. In a subset of cell lines, ARN-509 and enzalutamide exhibit agonist activity due to a missense mutation (F876L) in the ligand-binding domain of the androgen receptor (AR). AR F876L is sufficient to confer resistance to ARN-509 and enzalutamide in in vitro and in vivo models of castration-resistant prostate cancer (CRPC). Importantly, the AR F876L mutant is detected in plasma DNA from ARN-509–treated patients with progressive CRPC. Thus, selective outgrowth of AR F876L is a clinically relevant mechanism of second-generation antiandrogen resistance that can potentially be targeted with next-generation antiandrogens. Significance: A missense mutation in the ligand-binding domain of the androgen receptor F876L confers resistance to the second-generation antiandrogens enzalutamide and ARN-509 in preclinical models of AR function and prostate cancer and is detected in plasma DNA from ARN-509–treated patients with progressive disease. These results chart a new path for the discovery and development of next-generation antiandrogens that could be coupled with a blood-based companion diagnostic to guide treatment decisions. Cancer Discov; 3(9); 1020–9. ©2013 AACR. See related commentary by Nelson and Yegnasubramanian, p. 971 This article is highlighted in the In This Issue feature, p. 953
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 1×
“However, mutations in the ligand binding domain of AR have been described in 10 to 20 percent of patients who have progressed on the 1 generation anti-androgen therapies (4, 5).”
BackgroundDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Dressman, D., Yan, H., Traverso, G., Kinzler, K. W., & Vogelstein, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133470100 · Cited by 844
Heemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 662
Self-citationZhao, X.-Y., Malloy, P. J., Krishnan, A. V., Swami, S., Navone, N. M., Peehl, D. M., & Feldman, D. (2000) · Nature Medicine · doi:10.1038/76287 · Cited by 536
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 454
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., & Miyamoto, M. (2003) · PubMed · Cited by 425
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397 · cited 1×
“(20) recently described a forward genetic screen for AR mutations that confer agonist activity to enzalutamide.”
BackgroundRegulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364 · cited 1×
“15 Materials and Methods Cell culture and reagents LNCaP (ATCC, purchased 2009), LNCaP/AR(cs) (a LNCaP cell line engineered to overexpress wild-type AR 3- to 5-fold higher than the parental LNCaP cell line, gift from Charles Sawyers, 2009) (23) and LNCaP/AR-Luc (a LNCaP/AR(cs) cell line containing a stable integrated…”
MethodRathkopf, D. E., Morris, M. J., Fox, J. J., Danila, D. C., Slovin, S. F., Hager, J. H., Rix, P. J., Chow Maneval, E., Chen, I., Gönen, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.1684 · Cited by 261
Self-citationFunctional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Fenton, M. A., Shuster, T. D., Fertig, A., Taplin, M. E., Kolvenbag, G. J. C. M., Bubley, G. J., & Balk, S. P. (1997) · PubMed · Cited by 225
Kemppainen, J. A. (1999) · Molecular Endocrinology · doi:10.1210/me.13.3.440 · Cited by 207
Mechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204
O’Hare, T., Deininger, M. W., Eide, C. A., Clackson, T., & Druker, B. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3314 · Cited by 150
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
Foster, W. R., Car, B. D., Shi, H., Lévesque, P., Obermeier, M. T., Gan, J., Arezzo, J. C., Powlin, S. S., Dinchuk, J. E., Balog, A., et al. (2010) · The Prostate · doi:10.1002/pros.21263 · Cited by 120
(2000) · Nature Medicine · doi:10.1038/78716 · Cited by 94
Cardoso, W. V., & Kotton, D. N. (2008) · Cited by 66
Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists
Joseph, J. D., Wittmann, B. M., Dwyer, M. A., Cui, H. N., Dye, D. A., McDonnell, D. P., & Norris, J. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900185106 · Cited by 42
Self-citationTransgenic Mouse Model for Rapid Pharmacodynamic Evaluation of Antiandrogens
Ellwood‐Yen, K., Wongvipat, J., & Sawyers, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1397 · Cited by 35
Androgen receptor gene polymorphisms and alterations in prostate cancer: Of humanized mice and men
Robins, D. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.003 · Cited by 17
Cited by
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., Shah, N., Cai, L., Efstathiou, E., Logothetis, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.012 · Cited by 986
Metadata
- Authors
- Joseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., & Hager, J. H.
- Venue
- Cancer Discovery
- Published
- 2013-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 1020-1029
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2121846636
- Cited by
- 578
- References
- 27
- FWCI
- 49.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.